Zhao Yuejie, Singh Arunima, Li Lingyun, Linhardt Robert J, Xu Yongmei, Liu Jian, Woods Robert J, Amster I Jonathan
University of Georgia, Department of Chemistry, 140 Cedar Street, Athens, GA 30602-2556, USA.
Analyst. 2015 Oct 21;140(20):6980-9. doi: 10.1039/c5an00908a.
We validate the utility of ion mobility to measure protein conformational changes induced by the binding of glycosaminoglycan ligands, using the well characterized system of Antithrombin III (ATIII) and Arixtra, a pharmaceutical agent with heparin (Hp) activity. Heparin has been used as a therapeutic anticoagulant drug for several decades through its interaction with ATIII, a serine protease inhibitor that plays a central role in the blood coagulation cascade. This interaction induces conformational changes within ATIII that dramatically enhance the ATIII-mediated inhibition rate. Arixtra is the smallest synthetic Hp containing the specific pentasaccharide sequence required to bind with ATIII. Here we report the first travelling wave ion mobility mass spectrometry (TWIMS) investigation of the conformational changes in ATIII induced by its interaction with Arixtra. Native electrospray ionization mass spectrometry allowed the gentle transfer of the native topology of ATIII and ATIII-Arixtra complex. IM measurements of ATIII and ATIII-Arixtra complex showed a single structure, with well-defined collisional cross section (CCS) values. An average 3.6% increase in CCS of ATIII occurred as a result of its interaction with Arixtra, which agrees closely with the theoretical estimation of the change in CCS based on protein crystal structures. A comparison of the binding behavior of ATIII under both denaturing and non-denaturing conditions confirmed the significance of a folded tertiary structure of ATIII for its biological activity. A Hp oligosaccharide whose structure is similar to Arixtra but missing the 3-O sulfo group on the central glucosamine residue showed a dramatic decrease in binding affinity towards ATIII, but no change in the mobility behavior of the complex, consistent with prior studies that suggested that 3-O sulfation affects the equilibrium constant for binding to ATIII, but not the mode of interaction. In contrast, nonspecific binding by a Hp tetrasaccharide showed more complex mobility behavior, suggesting more promiscuous interactions with ATIII. The effect of collisional activation of ATIII and ATIII-Arixtra complex were also assessed, revealing that the binding of Arixtra provided ATIII with additional stability against unfolding. Overall, our results validate the capability of TWIMS to retain the significant features of the solution structure of a protein-carbohydrate complex so that it can be used to study protein conformational changes induced by the binding of glycosaminoglycan ligands.
我们利用抗凝血酶III(ATIII)和Arixtra(一种具有肝素(Hp)活性的药物)这一特征明确的系统,验证了离子淌度用于测量由糖胺聚糖配体结合所诱导的蛋白质构象变化的实用性。几十年来,肝素一直作为一种治疗性抗凝血药物,通过与ATIII相互作用发挥作用。ATIII是一种丝氨酸蛋白酶抑制剂,在血液凝固级联反应中起核心作用。这种相互作用会在ATIII内诱导构象变化,从而显著提高ATIII介导的抑制率。Arixtra是最小的合成肝素,含有与ATIII结合所需的特定五糖序列。在此,我们报告了首次利用行波离子淌度质谱(TWIMS)研究ATIII与Arixtra相互作用所诱导的构象变化。原生电喷雾电离质谱能够温和地转移ATIII和ATIII - Arixtra复合物的原生拓扑结构。对ATIII和ATIII - Arixtra复合物的淌度测量显示为单一结构,具有明确的碰撞截面(CCS)值。ATIII与Arixtra相互作用导致其CCS平均增加3.6%,这与基于蛋白质晶体结构对CCS变化的理论估计密切相符。对ATIII在变性和非变性条件下结合行为的比较证实了ATIII折叠的三级结构对其生物活性的重要性。一种结构与Arixtra相似但中心葡糖胺残基上缺少3 - O磺基的肝素寡糖,显示出对ATIII的结合亲和力显著降低,但复合物的淌度行为没有变化,这与先前的研究一致,即3 - O硫酸化影响与ATIII结合的平衡常数,但不影响相互作用模式。相比之下,一种肝素四糖的非特异性结合表现出更复杂的淌度行为,表明与ATIII存在更杂乱的相互作用。还评估了ATIII和ATIII - Arixtra复合物的碰撞活化效应,结果表明Arixtra的结合为ATIII提供了额外的抗解折叠稳定性。总体而言,我们的结果验证了TWIMS保留蛋白质 - 碳水化合物复合物溶液结构显著特征的能力,因此它可用于研究由糖胺聚糖配体结合所诱导的蛋白质构象变化。